Emyria Ltd · ASX:EMD
Emyria — ASA Virtual Investor Summit October 2023
24 slides from Emyria's conference presentation, Oct 27, 2023
Slide 1: Creating tomorrow's therapies from today's patient stories
For personal use only Creating tomorrow’s therapies from today’s patient stories (ASX:EMD) Investor Summit 27 October 2023 | mwinlo@emyria.com
Slide 2: Disclaimer to presentation
DISCLAIMER to presentation This presentation has been prepared by Emyria Limited ACN 625 085 734 (Company or Emyria). This presentation is not a financial product or investment advice or recommendation, offer or invitation by any person or to any person to sell or purchase securities in Emyria in any
Slide 3: Emyria | Corporate Structure
EMYRIA | CORPORATE STRUCTURE KEY METRICS VALUE Market Capitalisation ~A$25.5M Tenmile For personal use only Shares on Issue 349,226,509 7.8% Last reported cash A$2.14M (at 30 Sep 2023) Other Holdings Directors 27% Top 50 67.2% Emyria 2023 3
Slide 4: Integrated drug development & clinical services company
For personal use only Integrated drug development & clinical services company focussed on mental health, neuropsychiatry, and certain neurological conditions
Slide 5: Our Opportunity: The Rising Cost and Burden of Mental Health Care
OUR OPPORTUNITY | THE RISING COST AND BURDEN OF MENTAL HEALTH CARE Growing Mental Health Emerging Therapies Australia 1st to Burden Show Promise Legalise; 1 yr Headstart For personal use only Example: Psychedelic-assisted therapies: $225 Billion Annual US Spending (2019) 1 ~80+% of PTSD patients on
Slide 6: MDMA-Assisted Therapy for Post-Traumatic Stress Disorder
For personal use only MDMA-Assisted Therapy for Post-Traumatic Stress Disorder
Slide 7: What is Post-Traumatic Stress Disorder (PTSD)?
WHAT IS POST-TRAUMATIC STRESS DISORDER (PTSD)? 1 A chronic, debilitating mental health disorder that can occur following a traumatic event Current Affects ~1m Australians Symptoms Treatments with High Rates of For personal use only Resistance Re-experiencing: Intrusive memories, flashbacks, and night
Slide 8: Unique Psychopharmacological Effects of MDMA
UNIQUE PSYCHO- PHARMACOLOGICAL EFFECTS OF MDMA (“ecstasy”) For personal use only ● feelings of wellbeing ● sociability and extroversion ● interpersonal trust INCREASED AN ALERT STATE OF CONSCIOUSNESS DECREASED ● feelings of fear & defensiveness These effects suggest MDMA could be a promising adjunct
Slide 9: MDMA-AT Showing Remarkable Promise for PTSD
MDMA-AT SHOWING REMARKABLE PROMISE FOR PTSD | TWO PHASE 3 TRIALS COMPLETED 1, 2 Improves symptoms Improves function Key benefits after 3 treatment sessions MAPP1 MAPP1 For personal use only 86.5% of MDMA-AT participants reported improvement, compared to 69% in the placebo group. 71.2% of MDMA-AT part
Slide 10: The Problem: Very few clinical services can deliver these therapies
THE PROBLEM: For personal use only Very few clinical services are capable of delivering these therapies. & We need more evidence.
Slide 11: For personal use only
For personal use only “For approval to prescribe, psychiatrists will need to demonstrate: appropriate training, patient selection, evidence-based treatment protocols and patient monitoring. Further, ongoing psychotherapeutic support remains an essential component of the psychedelic treatment model.”
Slide 12: Emyria has done this before
For personal use only Emyria has done this before…. & has been preparing for years
Slide 13: Emyria Clinics: Already Delivering MDMA-AT in a Clinical Trial
EMYRIA CLINICS | ALREADY DELIVERING MDMA-AT IN A CLINICAL TRIAL 1 Assessing feasibility and cost-benefits to support payer engagement For personal use only o se a ry M A ved p D ly o l p ur inics i p n li am M e upp p pr ode r- cl isc al te cu r s s-a re m - fo d c Fit i l t inic Se i h ca M u cl Et
Slide 14: How Large is the Opportunity?
HOW LARGE IS THE OPPORTUNITY? 35% of Australian adults experienced at least 1 mental health challenge in the last 12 months 1 Market for For personal use only MDMA-AT for PTSD 2 Total Addressable Market (TAM) PTSD In any 12 month period, PTSD affects 6% of Anxiety disorders Australian adults (6%) (2
Slide 15: Emyria's Model for Impact & Growth
EMYRIA’S MODEL FOR IMPACT & GROWTH 1. Create Immediate 2. Scale 3. Create Long-term Impact Impact & Value For personal use only Use our proprietary data to improve Multidisciplinary clinics Add new services and grow via our care models and develop new providing best-in-class and strategic partnershi
Slide 16: Immediate Impact & Scale: Emyria Clinics
1. IMMEDIATE IMPACT & SCALE | EMYRIA CLINICS We’ve provided care for over 15,000 patients and are delivering strong billings growth (250%+ last quarter 1) For personal use only ● Physical clinics & telehealth ● 40+ clinical conditions ● 25+ clinicians (psychiatrists, GPs, mental health nurses, physi
Slide 17: Leveraging Our Data for Care Model & Drug Development
2. LEVERAGING OUR DATA FOR CARE MODEL & DRUG DEVELOPMENT PROGRAM DEVELOPMENT GOAL STAGE COMMERCIAL STATUS CATEGORY LEADER Ultra-Pure CBD Capsules | Highly bioavailable CBD For personal use only Partnered with ASPEN EMD-RX5 Pharmacy treatment for mild anxiety & stress Phase 3 clinical trials PHARMACA
Slide 18: Emyria Drug Development: Ultra-Pure CBD
EMYRIA DRUG DEVELOPMENT | ULTRA-PURE CBD We’ve developed multiple dose forms targeting registration as capsule medicines For personal use only EMD-RX5 EMD-RX7 EMD-RX9 EMD-MX1 EMD-MX1 EMD-MX1 An Ultra-Pure CBD capsule for High bioavailability Ultra-Pure CBD High potency, high bioavailability over-the
Slide 19: Emyria Drug Development: MDMA-Analogues
EMYRIA DRUG DEVELOPMENT | MDMA-ANALOGUES One of the world’s largest libraries of MDMA analogues developed with For personal use only Dopamine associated with feelings of pleasure and satisfaction Screened for selective Proprietary modulation of major Serotonin analogue library neurotransmitters thou
Slide 20: Emyria's Unique Model: Short-Term Impact & Long-Term Value Creation
EMYRIA’S UNIQUE MODEL | SHORT-TERM IMPACT & LONG-TERM VALUE CREATION 15,000 patients, innovative treatments, service revenues EMYRIA CLINICS For personal use only REAL - WORLD DATA millions of data points EMYRIA DRUG DEVELOPMENT novel MDMA analogues & Ultra-Pure CBD capsules Emyria 2023 20
Slide 21: Leaders in Care Delivery, Data and Drug Development
LEADERS IN CARE DELIVERY, DATA and DRUG DEVELOPMENT For personal use only CHAIRMAN NE-DIRECTOR E-DIRECTOR MANAGING DIRECTOR NE-DIRECTOR MEDICAL DIRECTOR Dr Stewart Washer Prof Sir John Tooke Dr Karen Smith Dr Michael Winlo Dr Mohit Kaushal C/Prof Alistair Vickery PhD (Microbiology) FRCP, FMedSci MD,
Slide 22: Our Roadmap
OUR ROADMAP # PROGRAM MILESTONE 1 MILESTONE 2 MILESTONE 3 OTHERS Emyria psychiatrists Complete patient Complete Phase For personal use only Begin MDMA-AT recruitment for 1 Deliver MDMA-AT treatment obtain Authorised Phase 2b trial 2b trial for Prescriber status MDMA (MDMA) Animal study results for A
Slide 23: Investment Highlights
(ASX:EMD) 7 INVESTMENT HIGHLIGHTS Australia is At the forefront Novel MDMA Unparalleled Clinics Unique CBD Experienced leading the of psychedelic analogue access to delivering dose forms management charge globally assisted library patient data revenue team in new treatment For personal use only trea
Slide 24: Contact Information
CONTACT INFORMATION For personal use only Michael Winlo mwinlo@emyria.com Investors investors@emyria.com Media media@emyria.com General info@emyria.com INVESTOR HUB: https://investorhub.emyria.com/